Lantus in Adolescents (Ages 12 to 17): Transitioning to Adult Diabetes Care

Why the Adolescent-to-Adult Transition Is a Clinical High-Risk Period

The years between 16 and 25 carry the highest rate of diabetes care disengagement of any age band. A 2018 analysis published in Diabetes Care (N=1,507 young adults with type 1 diabetes) found that A1C rose by a mean of 0.6% in the 12 months immediately following transfer to adult care, compared with the final 12 months of pediatric follow-up [1]. That figure may sound modest, but a sustained 0.6% A1C increase raises the 10-year risk of diabetic nephropathy by approximately 25% [2].

Lantus prescriptions are especially vulnerable during this window. Pediatric endocrinology practices use school-year appointment cycles; adult practices do not. A teen who aged out of a pediatric clinic in June and could not secure an adult appointment until October may go four months without dose adjustment, lab review, or CGM data download.

What Drives Disengagement

Three overlapping factors account for most transition failures:

• Structural gaps. Many pediatric practices discharge patients at age 18 regardless of whether an adult provider has been identified.
• Insurance changes. Coverage may shift from a parent's plan to Medicaid or a marketplace plan, sometimes mid-titration.
• Psychosocial load. College enrollment, new employment, and first independent living all compress the bandwidth available for chronic disease self-management.

A 2020 systematic review in BMJ Open (14 studies, N=3,842) documented that young adults with type 1 diabetes who experienced a care gap exceeding three months were 2.3 times more likely to present to an emergency department with diabetic ketoacidosis within two years [3].

The Pubertal Insulin Resistance Effect

Puberty itself alters Lantus requirements substantially. Growth hormone and IGF-1 surges during Tanner stages 3 to 5 increase insulin resistance by 30 to 50%, meaning a 14-year-old may need a significantly higher weight-based basal dose than the same patient at age 10 [4]. By age 17 to 18, as growth velocity declines, that resistance begins to resolve. An adult endocrinologist inheriting a patient from pediatric care may see a dose that looked appropriate at 16 but causes hypoglycemia at 19. Communicating the pubertal trajectory in the transition summary document is therefore clinically necessary, not optional.

Lantus Dosing in Adolescents: What Transfers to Adult Care

Standard Starting Dose Range

The FDA-approved prescribing information for Lantus states that in insulin-naïve patients with type 2 diabetes, basal therapy may begin at 0.2 units/kg/day once daily [5]. For adolescents with type 1 diabetes already established on a basal-bolus regimen, the basal fraction typically represents 40 to 50% of total daily insulin dose, giving a practical starting range of 0.2 to 0.4 units/kg/day for most teens.

A 14-year-old weighing 60 kg might require 15 to 20 units of Lantus at bedtime, while a 17-year-old male at 80 kg in mid-puberty could need 28 to 35 units to achieve fasting targets. Neither figure is wrong; both reflect the patient's developmental stage.

Titration Protocol During Transition

The "3-0-3" self-titration rule is widely used in adult endocrinology and can be introduced in the final 12 months of pediatric care as preparation for self-management:

• If fasting glucose exceeds 130 mg/dL on three consecutive mornings, increase the Lantus dose by 2 units.
• If fasting glucose falls below 80 mg/dL on any morning, decrease the dose by 2 units.
• Wait at least three days between adjustments.

This protocol originated in the TITRATE study, which showed that patient-led basal insulin titration achieved A1C reductions comparable to provider-led adjustment (mean A1C reduction 1.3% vs. 1.2%, P = 0.41) in adults with type 2 diabetes [6]. Teaching it proactively during late adolescence reduces the clinical danger of a post-transition dosing gap.

Injection Technique Reminders at Transfer

Adult care teams sometimes discover that a patient has been injecting Lantus into the same single site for years, producing lipohypertrophy that delays absorption by 30 to 60 minutes and blunts peak effect. The ADA's Standards of Medical Care in Diabetes (2024) recommend examining all injection sites at every clinic visit and rotating among at least three body regions [7]. The transition summary should document current site use.

A1C Targets Across the Transition Age Band

The American Diabetes Association sets an A1C goal of <7.0% for most adolescents aged 13 to 17, provided the target can be reached without recurrent severe hypoglycemia [7]. After age 18, the same threshold applies to most adults, though the 2024 ADA Standards allow individualization toward <8.0% in patients with hypoglycemia unawareness or limited life expectancy.

The table below maps ADA-recommended A1C targets to the transition age range and flags when individualization is appropriate.

| Age Band | ADA A1C Target | When to Individualize | |---|---|---| | 13 to 17 (pediatric) | <7.0% | Hypoglycemia unawareness, significant psychosocial burden | | 18 to 25 (young adult) | <7.0% | Same exceptions; add frequent alcohol use, disordered eating | | 26+ (adult) | <7.0% | Short diabetes duration, long life expectancy; <8.0% if comorbid |

A 2022 JAMA Internal Medicine analysis of 9,500 young adults (18 to 25) with type 1 diabetes found that A1C climbed from a pediatric mean of 7.8% to an adult mean of 8.5% within 24 months of care transfer, with the steepest rise in those who missed even one follow-up appointment [8]. That single missed visit carried an independent association with a 0.4% A1C rise after adjustment for confounders.

Structuring the Handoff: A Step-by-Step Framework

Step 1: Begin Preparation at Age 14 to 15

Transition planning should start no later than age 14. The American Academy of Pediatrics, American Academy of Family Physicians, and American College of Physicians joint clinical report recommends beginning health-care transition planning by age 12 to 14 for all youth with chronic conditions [9]. For a patient on Lantus, this means:

• Ensuring the adolescent can name their medications, doses, and injection sites without parental prompting.
• Teaching the "3-0-3" titration rule and confirming the patient can perform it independently.
• Starting a personal medication list the patient maintains themselves.

Step 2: Overlap Pediatric and Adult Care for at Least Six Months

A cold handoff, in which the pediatric team discharges the patient before an adult appointment is confirmed, is the single most preventable cause of transition failure. Best practice, endorsed by the International Society for Pediatric and Adolescent Diabetes (ISPAD), calls for at least one joint or parallel-visit period where both care teams are active [10].

During this overlap:

• The pediatric team sends a structured transition summary including current Lantus dose, titration history, CGM time-in-range data, last A1C, and all active comorbidities.
• The adult team accepts the patient before the pediatric discharge is finalized.
• Prescription continuity for Lantus (or its biosimilar) is confirmed before the first adult visit.

Step 3: Address Insurance and Pharmacy Continuity

Insulin cost is a documented driver of rationing. A 2019 JAMA Internal Medicine study found that 25% of adults with type 1 diabetes reported rationing insulin due to cost, and the 18 to 25 age band had the highest prevalence at 34% [11]. During the transition, the care team should:

• Verify the patient's post-18 insurance status at least 90 days before pediatric discharge.
• Enroll eligible patients in Sanofi's Insulins Valyou Savings Program or refer to state Medicaid formulary review.
• Confirm whether an approved glargine biosimilar (Basaglar, Semglee, Rezvoglar) is cost-equivalent on the new formulary.

Step 4: First Adult Endocrinology Visit Checklist

The first adult visit should occur within 90 days of pediatric discharge. At that visit, the adult provider should:

1. Review the transition summary and reconcile current Lantus dose against recent CGM or SMBG data.
2. Order an A1C and a complete metabolic panel if not done in the previous 90 days.
3. Screen for thyroid dysfunction (TSH) and celiac antibodies if not tested in the prior two years, as both are more common in type 1 diabetes and often go undetected during late adolescence.
4. Assess for diabetes distress using a validated tool such as the Problem Areas in Diabetes (PAID) scale.
5. Confirm injection site integrity and update rotation education if needed.

Biosimilars: What Adolescents and Their New Providers Need to Know

Three FDA-approved glargine biosimilars are now available in the United States: Basaglar (glargine-yfgn, Eli Lilly), Semglee (glargine-yfgn, Viatris), and Rezvoglar (glargine-yfgn, Eli Lilly). The FDA has designated Semglee as interchangeable with Lantus, meaning pharmacists may substitute it without a new prescription in states that permit interchangeable substitution [12].

For an adolescent transitioning to adult care, a formulary change from Lantus to a biosimilar is clinically acceptable provided:

• The unit-to-unit dose conversion is 1:1 (no dose adjustment is required).
• The patient is informed of the device change (SoloSTAR pen vs. KwikPen vs. Semglee pen).
• The transition summary documents which product the patient was using, so the adult team does not interpret a pen-device error as a dosing error.

A 2021 FDA review confirmed equivalent pharmacokinetic profiles for approved glargine biosimilars, with no clinically meaningful differences in time-action curves at therapeutic doses [12].

CGM and Technology Continuity

Continuous glucose monitoring (CGM) has changed the practical meaning of "Lantus management" for adolescents. Time-in-range (TIR, glucose 70 to 180 mg/dL) is now the primary metric many pediatric teams use for dose adjustment. The ADA recommends a TIR target of >70% for most patients with type 1 diabetes, corresponding roughly to an A1C of <7.0% [7].

The DIAMOND trial (N=158, randomized controlled) showed that CGM use in adults with type 1 diabetes on multiple daily injections reduced A1C by 1.0% vs. 0.4% in the control group at 24 weeks (P<0.001) [13]. That benefit depends entirely on whether the patient keeps the same device across the transition.

Device continuity is frequently broken during care transfer. The adult practice may use a different CGM brand, or the new insurance formulary may not cover the pediatric device. Confirming CGM formulary coverage before discharge is as important as confirming Lantus coverage.

Monitoring Targets and Lab Schedule After Transition

Adult endocrinology practices follow a different monitoring cadence than pediatric practices. The 2024 ADA Standards recommend [7]:

• A1C: every 3 months if not at goal; every 6 months if stable at <7.0%.
• Lipid panel: annually.
• Urine albumin-to-creatinine ratio: annually starting at puberty onset or 5 years after type 1 diabetes diagnosis.
• Dilated eye exam: annually (or every 2 years if consistently A1C <7.0% and no retinopathy on prior exam).
• Blood pressure: at every visit; target <130/80 mmHg.
• Foot exam: annually for type 1, and at every visit if peripheral neuropathy symptoms are present.

Adolescents transferring at age 17 to 18 may already have 5 to 10 years of type 1 diabetes duration, placing them squarely in the window where early nephropathy and background retinopathy screening is overdue rather than premature.

Psychosocial Support During the Transition Year

Diabetes distress affects 33 to 45% of young adults with type 1 diabetes, according to a 2018 review in Diabetes Care [14]. It is distinct from clinical depression but is associated with A1C values that are 0.5 to 1.2% higher than in patients without distress. Lantus non-adherence (skipping injections, under-dosing to avoid hypoglycemia, stockpiling doses) is a common behavioral marker of unaddressed distress.

The adult care team should ask directly: "Have you skipped or reduced your Lantus in the past 30 days?" A yes answer requires a brief intervention before the focus shifts to dose titration. Referring to a diabetes care and education specialist (DCES) or a psychologist with diabetes experience is appropriate for patients who confirm injection skipping.